Holen Sie sich die Stockscreener-App
2.48
1.20%
-0.01
Schlusskurs vom Vortag:
$2.49
Offen:
$2.5
24-Stunden-Volumen:
70,408
Relative Volume:
0.15
Marktkapitalisierung:
$558.60M
Einnahmen:
$58.17M
Nettoeinkommen (Verlust:
$-281.50M
KGV:
-1.5854
EPS:
-1.5643
Netto-Cashflow:
$-349.78M
1W Leistung:
-7.87%
1M Leistung:
-11.19%
6M Leistung:
-25.23%
1J Leistung:
-55.19%
1-Tages-Spanne:
$2.41
$2.5376
1-Wochen-Bereich:
$2.37
$2.675
52-Wochen-Spanne:
$2.215
$6.30
Curevac N V Stock (CVAC) Company Profile
Vergleichen Sie CVAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CVAC | 2.48 | 558.60M | 58.17M | -281.50M | -349.78M | -1.5643 |
| VRTX | 446.09 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.70 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 250.25 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-19 | Hochstufung | UBS | Neutral → Buy |
| 2023-01-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-01-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-06-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Underperform |
| 2021-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2020-12-10 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | Eingeleitet | BofA Securities | Buy |
| 2020-09-08 | Eingeleitet | Credit Suisse | Neutral |
| 2020-09-08 | Eingeleitet | Jefferies | Hold |
Alle ansehen
Curevac N V Aktie (CVAC) Neueste Nachrichten
CureVac NV (FRA:5CV) Retained Earnings : €-1,371.0 Mil (As of Sep. 2024) - GuruFocus.com
CureVac NV (HAM:5CV) 3-Year Revenue Growth Rate : -16.20% (As of Sep. 2024) - GuruFocus.com
CureVac NV (FRA:5CV) EBITDA : €165.9 Mil (TTM As of Sep. 2024) - GuruFocus.com
CureVac’s stock soars on GSK’s $1.56 billion deal for its COVID-19 and flu vaccines - MSN
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock? - Yahoo Finance
10 Best German Stocks To Buy Now - Insider Monkey
Is CureVac N.V. (CVAC) the Best German Stock to Buy Now? - Insider Monkey
CureVac NV (HAM:5CV) 3-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
CVAC (CureVac NV) Short-Term Capital Lease Obligation : $5.46 Mil (As of Jun. 2024) - GuruFocus.com
mRNA Vaccine and Therapeutics Market 2024-2031: Global - openPR
CureVac NV earnings beat by €0.09, revenue topped estimates - Investing.com Canada
CureVac N.V. (NASDAQ:CVAC) Q3 2024 Earnings Call Transcript - Insider Monkey
CureVac NV (CVAC) Q3 2024 Earnings Call Highlights: Strong Financial Performance and Strategic ... - Yahoo Finance
CureVac Reports Significant Revenue Growth Amid Strategic Restructuring - TipRanks
CureVac Reports Surging Revenues and Profit Growth - TipRanks
CureVac on track with 30% workforce reduction - TipRanks
CureVac reports Q3 revenue EUR 493.9M vs. EUR 16.5M last year - TipRanks
CureVac sees cash runway into 2028 - TipRanks
CureVac Announces Financial Results for the Third Quarter and Fi - WICZ
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update - AccessWire
CureVac Surges on €400M GSK Deal, Reports 77% Success in Cancer Trial | CVAC Stock News - StockTitan
CureVac (CVAC) Set to Announce Earnings on Tuesday - MarketBeat
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 - AccessWire
CureVac NV (LTS:0A9E) EBITDA : $-275.09 Mil (TTM As of Jun. 2024) - GuruFocus.com
CureVac appoints new CFO to drive growth By Investing.com - Investing.com Canada
CureVac’s Latest mRNA Advances Spark Investor Interest - TipRanks
CureVac Appoints Chief Financial Officer - Contract Pharma
CureVac appoints new CFO to drive growth - Investing.com
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer - AccessWire
CureVac to Present at the 12th International mRNA Health Conference - AccessWire
CVAC (CureVac NV) Change In Inventory : $-45.98 Mil (TTM As of Jun. 2024) - GuruFocus.com
CVAC (CureVac NV) 3-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
CureVac NV (HAM:5CV) Free Cash Flow : €-330.26 Mil (TTM As of Jun. 2024) - GuruFocus.com
CureVac (NASDAQ:CVAC) Trading 3.9% HigherStill a Buy? - MarketBeat
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - AccessWire
mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way - GlobeNewswire Inc.
Setback for CureVac in the UK - JUVE Patent
CureVac (NASDAQ:CVAC) Shares Gap UpTime to Buy? - MarketBeat
CureVac Stock: Back To Square One (NASDAQ:CVAC) - Seeking Alpha
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents - Marketscreener.com
Point72 Asset Management L.P. Invests $8.24 Million in CureVac (NASDAQ:CVAC) - MarketBeat
CureVac N.V.'s (NASDAQ:CVAC) top owners are individual investors with 35% stake, while 31% is held by private equity firms - Yahoo Finance
Wall Street SWOT: CureVac stock navigates mRNA frontier amid restructuring - Investing.com
mRNA Vaccine and Therapeutics Market Global Report to 2035, with Profiles of Arcturus Therapeutics, BioNTech, CureVac, Ethris, Immorna, Moderna, Providence Therapeutics and Suzhou Abogen Biosciences - Yahoo Finance
Curefoods in talks to raise $40 million in Series D round of funding, eyes IPO in 18 months - Moneycontrol
C.H. Robinson Sells European Division in $1.5B Deal: Strategic Shift to North America - Tank Transport Trader
“CURED” screening highlights important LGBTQ+ issues - The Wayne Stater
Hood River Capital Management LLC Raises Stake in Caesars Entertainment, Inc. (NASDAQ:CZR) - Defense World
Caesars Entertainment, Inc. (NASDAQ:CZR) Shares Bought by Hsbc Holdings PLC - Defense World
Legendary 80s Band Makes Epic Comeback with First New Album in 16 Years—Spotted at Local Pub!Central - Central Recorder
Gurugram Based CurveAi, Raises Capital from a Swiss Family Office Fund - Business Standard
Finanzdaten der Curevac N V-Aktie (CVAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):